Sentence examples for intermediate dose and from inspiring English sources

Four hours after inoculation, each wound was scrubbed for 30 seconds with 20% poloxamer 188 and then irrigated with 100 mL of one of four solutions: normal saline solution (control); cefazolin (CZ) 2 mg/mL, plus penicillin G (PCN) 200 units/mL (low dose); CZ 10 mg/mL, plus PCN 2,000 units/mL (intermediate dose); and CZ 50 mg/mL, plus PCN 20,000 units/mL (high dose).

Thrombocytopenia was also observed in the intermediate dose and high dose cohorts.

In a human patient we might consider <106 U IL-2 as low dose, (1 18) × 106 U as intermediate dose, and >18 × 106 U IL-2 high dose for local IL-2 application.

Serum aspartate transaminase (AST) levels rose above 500 U/ml at both the intermediate dose and the high dose, and bilirubin levels rose above 85·5 μmol/l in the high dose cohort only (Lozier et al, 1999).

The correspondence between SIMS and RBS profiles suggests that the atomic density of implanted layers increases from 1.5 to 2.2 g/cm3 at intermediate doses and returns to 1.7 g/cm3 at a high dose.

The multi-metal batch experiments showed the adsorption sequence Pb≈Cu>Cd>Zn>Ni for lower metal doses, Pb>Cu>Cd>Zn>Ni for intermediate doses, and Pb>Cu>Cd≈Zn≈Ni for high metal doses.

When flies are exposed to volatilized cocaine, they show similar behavioral effects including continuous grooming at low doses, circling and aberrant walking behavior at intermediate doses, and fast, uncontrolled movements followed by body tremors and akinesia at high doses (McClung and Hirsh 1998).

To determine which responses could be considered statistically nonmonotonic, we assessed whether the peak response of a given parameter occurred at one of the intermediate doses and whether the peak response could be statistically distinguished from the response at the highest dose.

This profile, also called inverted-U shape, is characterized by responses at intermediate dose (s) and a decreased response or no response observed at low- and high-exposure levels.

BKT140 (Biokine Therapeutics, Rehovot, Israel) is another promising high affinity CXCR4 inhibitor that has been tested in a phase I/IIa trial in multiple myeloma patients in combination with intermediate dose cyclophosphamide and G-CSF.

Thus, the placebo-corrected mean glycated hemoglobin decrease was −0.11, −0.44, and −0.85% after 1, 2, and 3 months, respectively, between the intermediate-dose and placebo/low-dose groups.